Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 April 2022
Seminar on Open Science

Publishing academic content behind a paywall not only limits access to scholarly work, but also prevents research output from being visible and making maximum impact. Researchers are paying to publish their research output, and libraries are paying to access it in what is known as double-dipping by publishers, leading to what we term ‘serial crisis’. Research institutions pay twice and still do not see their research widely available to be read.

By signing the Berlin Declaration on Open Access in 2012, the University of the Free State (UFS) committed itself to supporting open access to its research outputs. National initiatives by research institutions and the government make research outputs freely available via national site licensing. The UFS supports this initiative via the South African National Library and Information Consortium (SANLiC) as an interim transformative agreement with publishers, allowing research outputs to be open access, without the additional publication charges.

What do we do about publishers who are unwilling to transform? Do we still pay their massive subscription and publication fees? What do we need to do to ensure that all UFS research outputs are accessible to all?

Topic: Should the UFS continue to subscribe to academic journals that are behind a paywall?
Thursday 12 May 2022
12:00-13:30

Microsoft Teams
RSVP: Elma Viljoen, viljoene@ufs.ac.za (link will be provided)

Join the following top experts for what promises to be an insightful discussion:

  • Colleen Campbell
    Coordinator: Open Access 2020 Initiative
    Max Planck Digital Library, Munich, Germany
  • Ellen Tise
    Senior Director: Library and Information Services, Stellenbosch University

  • Glenn Truran
    Director: South African National Library and Information Consortium (SANLiC)

The welcoming and introduction to the webinar will be conducted by Prof Corli Witthuhn, Vice-Rector: Research.  

Bios of speakers

Colleen Campbell leads external engagement in the open access transition at the Max Planck Digital Library (MPDL) in Munich, Germany. There, she coordinates the Open Access 2020 Initiative, a global alliance of research organisations and their libraries that are driving the transition of today’s scholarly journals to open-access publishing models, and the ESAC Initiative, an international community of practice dedicated to optimising open-access workflows and processes. She is a member of the LIBER Open Access Working Group, serves on the Managing Board of EIFL, a not-for-profit organisation that works with libraries to enable access to knowledge in developing and transition economy countries in Africa, Asia-Pacific, Europe, and Latin America, and contributes to the advisory groups of a number of other scholarly communication initiatives.

Ellen Tise has been the Senior Director of Library and Information Services at Stellenbosch University (SU) since January 2006. She previously held the positions of University Librarian at the University of the Western Cape (UWC) and Deputy University Librarian at the University of the Witwatersrand. She holds a BBibl Honours degree from the UWC and an MPhil in Science and Technology Studies from SU. Among other notable leadership roles, Ms Tise served as the first President of the Library and Information Association of South Africa (LIASA) from 1998 to 2002, and President of the International Federation of Library Associations and Institutions, known as IFLA, for the years 2009 through 2011. She also served as Chair of the Board of the National Library of South Africa (2012-2015), and on the OCLC Board of Trustees (2014-2018). She has just started a second two-year term as Chair of the Freedom of Access to Information and Freedom of Expression Advisory Committee of IFLA. She is the recipient of several awards for distinguished leadership and outstanding contributions to librarianship, including honorary membership of LIASA and an honorary IFLA fellowship. She has published various articles in professional journals and is a regular speaker at national and international conferences, seminars, symposia, etc.

Glenn Truran has been the Director of the South African National Library and Information Consortium (SANLiC) since 2014 and works from home in Cape Town. After graduating from the University of the Witwatersrand (Wits) with a BA and HDipEd (PG), he worked briefly as an educator in South Africa and England. Subsequently, he completed a diploma in Public Policy and Development Administration at Wits and received his MBA from the University of Cape Town in 2003. Before joining SANLiC, he worked in several educational and poverty alleviation non-profit organisations in Gauteng and Cape Town. He has been actively involved in SANLiC’s Open Access Transformational Agreements task team.

Charlie Molepo has been the Deputy Director at the UFS Sasol Library responsible for Research and Scholarly Communications since 2015. He represents the non-academic staff on the University Council and serves on its Finance and Human Resources Committees. Before joining the UFS, he worked at Vista University, the University of Natal, the University of Johannesburg, the University of KwaZulu-Natal Libraries, and Dawson Books UK (Betrams) as the International Account Director for Africa. He serves as President-Elect (2022-2023) in the Library and Information Association of South Africa (LIASA).

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept